Futura Medical due $5m milestone payment from Haleon
Futura Medical
31.95p
16:55 20/12/24
-2.44%
-0.80p
Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been triggered under its agreement with consumer products giant Haleon.
FTSE 100
8,084.61
17:04 20/12/24
n/a
n/a
FTSE 350
4,463.29
17:14 20/12/24
n/a
n/a
FTSE AIM All-Share
710.60
17:04 20/12/24
n/a
n/a
FTSE All-Share
4,421.11
17:04 20/12/24
n/a
n/a
Haleon
381.10p
16:34 20/12/24
0.13%
0.50p
Pharmaceuticals & Biotechnology
19,761.12
17:14 20/12/24
0.06%
12.71
The AIM-traded firm said the milestone followed the successful distribution of online pre-orders and the availability of Eroxon in US retail stores.
It said the payment was expected to be received shortly.
Eroxon, Futura’s flagship product, is a clinically-proven sexual health product.
The milestone payment was another key step in its ongoing strategy to commercialise its products globally, with the US launch being a major milestone in the product’s growth.
At 1356 BST, shares in Futura Medical were up 2.77% at 33.45p.
Reporting by Josh White for Sharecast.com.